Please login to the form below

Not currently logged in
Email:
Password:

Industry too cautious about drug use during pregnancy

RCGP doctor says women are missing out on vital treatments due to overly cautious drug labelling

Pregnant women are being denied useful medicines because pharmaceutical companies are overly cautious in issuing safety warnings about them, a leading UK doctor has claimed.

Dr Jim Kennedy, head of prescribing at the Royal College of GPs, said some women were actually risking their health more by not being treated in the best way.

ìWomen are being denied use of drugs for everything from headaches and depression to infections,î he said. ìFor some drugs such as statins for cholesterol and some anti-epilepsy drugs, the risk of not taking medicine may be greater than the risk of taking them.î

The industry has been cautious about pregnant women taking medications since the thalidomide tragedy in the late 1950s and early 1960s, which resulted in 400 disabled babies being born in the UK.

Dr Kennedy said the situation had become so bad that many women avoided taking paracetamol even though most over-the-counter (OTC) drugs are safe to use.

ìWe should encourage women to consult with their doctors about whether they could be taking drugs,î he added.

Association of the British Pharmaceutical Industry (ABPI) spokesman Richard Ley said that the industry did err on the side of caution because patient safety is ìparamountî.

It has become almost standard practice for pharma firms to add caveats about the use of their products in pregnant women despite the fact that it is very rare for clinical trials to include expectant mothers.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics